| Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. | |
| | |
MedLine Citation:
|
PMID: 20635904 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer. |
| | |
Authors:
|
Myriam N Bouchlaka; Doug Redelman; William J Murphy |
Related Documents
:
|
16111464 - Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. 23046034 - Landmarks in prostate cancer screening. 74354 - Retroviruses and cancer. 18259184 - Interleukin 21: combination strategies for cancer therapy. 23166824 - Hyaluronan (ha) interacting proteins rhamm and hyaluronidase impact prostate cancer cel... 7667564 - A proportional regression model for 20 year survival of colon cancer in norway. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Immunotherapy Volume: 2 ISSN: 1750-7448 ISO Abbreviation: Immunotherapy Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-07-19 Completed Date: 2010-10-29 Revised Date: 2013-05-29 |
Medline Journal Info:
|
Nlm Unique ID: 101485158 Medline TA: Immunotherapy Country: England |
Other Details:
|
Languages: eng Pagination: 399-418 Citation Subset: IM |
Affiliation:
|
Department of Microbiology & Immunology, University of Nevada, Reno, NV, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Combined Modality Therapy Disease Models, Animal Graft vs Host Disease / immunology, prevention & control* Graft vs Tumor Effect / immunology Hematopoietic Stem Cell Transplantation / methods* Humans Immunotherapy, Adoptive / methods* Neoplasms / immunology, therapy* Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA095572-09/CA/NCI NIH HHS; R01 CA102282-09/CA/NCI NIH HHS |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Present state of target therapy for disseminated renal cell carcinoma.
Next Document: Acknowledgements.